Skip to main content

/ Technology/ Group items tagged #ESMO_Congress_2019

Group items tagged

Filter: All | Bookmarks | Topics Simple Middle

ESMO 2019: Seven promising digital health intervention companies participating in ESMO - 1 views

www.pharmaceutical-technology.com/...-health-intervention-companies

#ESMO_2019 #ESMO_Conference_2019 #ESMO_Congress_2019 #Digital_Health #ESMO_2019_Meeting

shared by jacob logan on 27 Sep 19 - No Cached

jacob logan on 27 Sep 19

Digital health interventions (DHIs) are fast emerging as vital tools to promote personal health and provide essential services. DHIs can be accessed through mobile phones, tablets and computers, as well as serve as effective support systems to improve personal health.

<div class="cArrow"> </div><div class="cContentInner"> Digital health interventions (DHIs) are fast emerging as vital tools to promote personal health and provide essential services. DHIs can be accessed through mobile phones, tablets and computers, as well as serve as effective support systems to improve personal health.</div>

...

Cancel

ESMO 2019: Seven promising liquid biopsy companies at ESMO Congress - 1 views

www.medicaldevice-network.com/...o-2019-liquid-biopsy-companies

#Liquid_Biopsy #ESMO_2019 #ESMO_Congress #Medical_Device #esmo_congress_2019 #esmo_conference_2019 #esmo_2019_dates #esmo_2019_meeting

shared by jacob logan on 27 Sep 19 - No Cached

jacob logan on 27 Sep 19

Liquid biopsy, a minimally invasive cancer diagnostic tool, has gained momentum in the last five years due to its advantages over the archaic painful procedure of solid tumour biopsy.

<div class="cArrow"> </div><div class="cContentInner">Liquid biopsy, a minimally invasive cancer diagnostic tool, has gained momentum in the last five years due to its advantages over the archaic painful procedure of solid tumour biopsy.</div>

...

Cancel

ESMO 2019: Kisqali shows superior overall survival in breast cancer - 1 views

www.clinicaltrialsarena.com/...esmo-novartis-kisqali

#ESMO_2019 #esmo_conference_2019 #esmo_congress_2019 #Breast_Cancer #esmo_2019_dates

shared by jacob logan on 07 Oct 19 - No Cached

jacob logan on 07 Oct 19

Novartis has said that Kisqali delivered superior overall survival (OS) in the Monaleesa-3 trial, demonstrating more life for postmenopausal human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer patients.

<div class="cArrow"> </div><div class="cContentInner">Novartis has said that Kisqali delivered superior overall survival (OS) in the Monaleesa-3 trial, demonstrating more life for postmenopausal human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer patients.</div>

...

Cancel

ESMO 2019: Ovarian cancer drug fails to meet primary endpoint in study - 1 views

www.clinicaltrialsarena.com/...esmo-immunogen

#ESMO_2019 #ESMO_Conference_2019 #ESMO_Congress_2019 #Digital_Health #ESMO_2019_Meeting

shared by jacob logan on 10 Oct 19 - No Cached

jacob logan on 10 Oct 19

ImmunoGen has presented full data from the Phase III Forward I study of mirvetuximab soravtansine in ovarian cancer at the European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona, Spain, saying that it failed to meet the primary endpoint of progression-free survival (PFS).

<div class="cArrow"> </div><div class="cContentInner">ImmunoGen has presented full data from the Phase III Forward I study of mirvetuximab soravtansine in ovarian cancer at the European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona, Spain, saying that it failed to meet the primary endpoint of progression-free survival (PFS).</div>

...

Cancel

ESMO 2019: Delegates told refractory metastatic renal cell carcinoma is an unmet need w... - 1 views

www.clinicaltrialsarena.com/...ell-carcinoma-therapy-advances

#ESMO_2019 #ESMO_Conference_2019 #ESMO_Congress_2019 #Delegates #Renal_Cell_Carcinoma #Refractory_Metastatic

shared by jacob logan on 17 Oct 19 - No Cached

jacob logan on 17 Oct 19

Despite advances in the renal cell carcinoma (RCC) therapy landscape, the majority of patients with RCC will eventually develop resistance to available therapies and the disease will progress through several stages, requiring further lines of treatment.

<div class="cArrow"> </div><div class="cContentInner">Despite advances in the renal cell carcinoma (RCC) therapy landscape, the majority of patients with RCC will eventually develop resistance to available therapies and the disease will progress through several stages, requiring further lines of treatment. </div>

...

Cancel

1 - 5 of 5

Showing 20▼ items per page

Related searches